Literature DB >> 24328885

Hypothalamic hamartoma: is the epileptogenic zone always hypothalamic? Arguments for independent (third stage) secondary epileptogenesis.

Julia Scholly1, Maria-Paola Valenti, Anke M Staack, Karl Strobl, Thomas Bast, Pierre Kehrli, Bernhard J Steinhoff, Edouard Hirsch.   

Abstract

Gelastic seizures associated with hypothalamic hamartomas (HHs) are a clinicoradiologic syndrome presenting with a variety of symptoms, including pharmacoresistant epilepsy with multiple seizure types, electroencephalography (EEG) abnormalities, precocious puberty, behavioral disturbances, and progressive cognitive deterioration. Surgery in adults provides seizure freedom in only one third of patients. The poor results of epilepsy surgery could be explained by an extrahypothalamic epileptogenic zone. The existence of an independent, secondary epileptogenic area with persistent seizures after resection of the presumably primary lesion supports the concept of a "hypothalamic plus" epilepsy. "Hypothalamic plus" epilepsy could be related to either an extrahypothalamic structural lesion (visible on magnetic resonance imaging [MRI] or on neuropathology) or if the former is absent, to a functional alteration with enhanced epileptogenic properties due to a process termed secondary epileptogenesis. We report two patients with gelastic seizures with HH (gelastic seizures isolated or associated with dyscognitive seizures of temporal origin). Both patients underwent two-step surgery: first an endoscopic resection of the HH, followed at a later time by temporal lobectomy. Both patients became seizure-free only after the temporal lobectomy. In both cases, neuropathology failed to demonstrate a significant structural lesion in the temporal lobe. To our knowledge, for the first time, these two cases suggest the existence of independent secondary epileptogenesis in humans. Wiley Periodicals, Inc.
© 2013 International League Against Epilepsy.

Entities:  

Keywords:  Epilepsy; Hypothalamic hamartoma; Secondary epileptogenesis; Surgery

Mesh:

Substances:

Year:  2013        PMID: 24328885     DOI: 10.1111/epi.12456

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  6 in total

1.  Hypothalamic hamartoma associated with polymicrogyria and periventricular nodular heterotopia in children: report of three cases and discussion of the origin of the seizures.

Authors:  Martine Fohlen; Delphine Taussig; Jerry Blustajn; Serge Rivera; Tom Pieper; Sarah Ferrand-Sorbets; Georg Dorfmuller
Journal:  Childs Nerv Syst       Date:  2022-06-10       Impact factor: 1.532

2.  Hypothalamic hamartomas in adulthood: Clinical spectrum and treatment outcome-A unicenter experience.

Authors:  Estefanía Conde Blanco; Carla Anciones Martín; Isabel Manzanares; Francisco Gil López; Pedro Roldán; Antonio Donaire; Jordi Rumiá; Mar Carreño
Journal:  Brain Behav       Date:  2019-10-02       Impact factor: 2.708

3.  fMRI functional connectivity as an indicator of interictal epileptic discharges.

Authors:  Jianpo Su; Hui Ming Khoo; Nicolás von Ellenrieder; Ling-Li Zeng; Dewen Hu; François Dubeau; Jean Gotman
Journal:  Neuroimage Clin       Date:  2019-10-23       Impact factor: 4.881

4.  Anatomical features decide the atypical seizure manifestation of parahypothalamic hamartomas.

Authors:  Chang Liu; Wenhan Hu; Chao Zhang; Zhong Zheng; Xiaoli Yang; Xiu Wang; Jiajie Mo; Zhihao Guo; Xiaoqiu Shao; Kai Zhang
Journal:  Front Neurol       Date:  2022-09-12       Impact factor: 4.086

5.  Disabling amnestic syndrome following stereotactic laser ablation of a hypothalamic hamartoma in a patient with a prior temporal lobectomy.

Authors:  Sarah Zubkov; Victor A Del Bene; William S MacAllister; Timothy M Shepherd; Orrin Devinsky
Journal:  Epilepsy Behav Case Rep       Date:  2015-08-10

6.  Electrophysiological properties and seizure networks in hypothalamic hamartoma.

Authors:  Di Wang; Yongzhi Shan; Fabrice Bartolomei; Philippe Kahane; Yang An; Muyang Li; Huaqiang Zhang; Xiaotong Fan; Siqi Ou; Yanfeng Yang; Penghu Wei; Chao Lu; Yihe Wang; Jialin Du; Liankun Ren; Yuping Wang; Guoguang Zhao
Journal:  Ann Clin Transl Neurol       Date:  2020-04-16       Impact factor: 4.511

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.